Newport Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) — The pressing need for business to continue through pandemic times is nowhere more evident than in the sales and marketing arena. Kovach Marketing, an industry expert in branding and online communications for the home building and related industries, saw early on that video conferencing was to become a mainstay of conducting business, connecting builders to homebuyers and vendors to customers both immediately and for the future. Successful companies did their homework, practiced within their organization and quickly shorten the learning curve to opening up the lines of communication.
“This shift has required creativity, problem-solving, reality-based operational effectiveness, emerging technology and the formation of new habits,” said Dana Kovach, President and CEO of Kovach Marketing. “Over the past five months, video conferences have gone from clumsy to cool, streamlined and preferred by many, but continually in need of refinement and improvement. We’ve just begun to experience the new advantages it offers, enabling a broader range of attendees to participate, reducing travel time and expense, and discovering that more can be accomplished when participants are properly prepared and equipped to conduct a great conference. We believe video conferencing is a new staple in business, and it’s essential to know how to make it work for you.”
Kovach Marketing points to the availability of access to a business conference and emerging technology as one of the first benefits of platform use. Younger workers have already embraced these platforms and rely on them on a daily basis. For those who are now becoming involved, they welcome the opportunity to participate with desktop, laptop or smartphone, thus promoting wider participation leading to successful collaboration and consensus. Larger and higher quality screens and new software to create room apps will transform the platform and reduce the need for a designated meeting room.
Another first step is determining which platform fits your business. The all-in-one hosting platforms, such as WebEx, Zoom, Microsoft Teams and Google Hangouts are fashioned for flexibility and global reach. These and others offer screen sharing capabilities accessible to remote teams, wherever they may be. Screen sharing is a must-have in any video conference, and according to Techradar.com, some platforms perform better than others. In addition, Artificial Intelligence is being advanced as a way to reduce background noise, improve focus on a speaker or displays, transcribe meeting notes and more.
Techradar points out “Normal consumer offerings such as Apple’s Facetime, WhatsApp Video and Zoom have made video communications a normalized part of the conversation process, especially as alternatives to Skype. The expectation is that businesses will increasingly embrace conferencing and webinar software simply because it offers so many all-round benefits, especially when using the best conference phones to ensure good quality communications.”
As video conferencing becomes commonplace as its capabilities are being increased and refined. Staying in step with these hardware and software milestones may feel overwhelming, yet there are experts who can help guide you in making intelligent, effective advancements. It’s essential to check out their different offerings to determine the right fit for your goals. Whether searching for a free platform or comparing capabilities and graduated price structures, it’s important to do the homework, starting with identifying experienced experts who can help shape the way you make decisions and do business in the future.
Being meeting-ready is as fundamental to a good meeting today as ever, but now even more so. Block out time on your calendar, gather materials, and check your setting before dial-in. Also, check the mirror because appearances matter. Your waist-up wardrobe must be neat, clean and professional – no exceptions. Dressing for business conveys a lot about you. Being onscreen reinforces your professionalism, so think twice before choosing not to be on camera. Video conferencing carries with it the ability to convey non-verbal cues that texts and emails lose.
Refining how your video conference is conducted is the key to success. Use screen-sharing to show specifics about workflows, projects, timelines, etc. Training and collaboration work well in this setting when everyone is on the same page.
Reduce background noise and visual distractions. Bad audio is one of the biggest complaints that plague video conferencing. Apps like Krisp quiet the ambient noise, while headsets with built-in microphones go a long way to improving your conference for yourself and others. Avoid situating yourself in a distracting environment. Keep the background neutral, avoid bright light or direct sun and minimize passers-by. Silence your phone as you would with an in-person meeting.
Make the meeting your focus and stay on topic. Stay present and put yourself front and center without slouching or sliding out of frame. Maintaining eye contact with attendees throughout the call keeps you presenting yourself as attentive, focused, professional and connected. A great deal of nuance and tone are conveyed in video conferencing, so be aware of your personal actions. Giving in to distractions distracts others and reflects poorly on you. If you’re distracted by your own face, you can try turning off self-view momentarily, especially if you’re in a one-on-one. Remember, the video part of the platform is what differentiates it from a voice call.
Good lighting makes a good impression. Aim to light the face by keeping the light or window directly in front of you. Natural light is just that, natural, but when needed, artificial lighting should be LED. Try placing one in front of you and another behind without putting either in the direct line of the camera. It pays to play around with your lighting to get the best effects.
There’s a special kind of etiquette for video conferencing that has a big impact on how well business is conducted and your performance is perceived. Muting your microphone is the first rule to observe faithfully. Mute when you’re not speaking, mute especially if you’re using your keyboard for notetaking. If you need to step away from your conference or meeting, use the chat function to tell everyone that you’ll be right back, then mute yourself and shut off video while you’re away from your device.
There are promising big picture changes that will take place for business during the pandemic, and at their core will be use of video conferencing, whether in a group or team meetings or one on one. The benefits are just beginning to show up, and will grow exponentially as the platform technology improves. Now is the right time to become aware, informed and engaged in making the platform a central part of your business. It’s definitely here to stay, and that’s a very good thing.
Kovach Marketing specializes in branding and marketing, focused on master-planned communities, new homes and related industries. The firm, comprised of a group of multidimensional, multi-talented professionals, was founded over 30 years ago by Dana Kovach, a communications veteran who has spearheaded the branding for Fortune 500 companies, best-in-class firms, start-ups and more. Driven by infectious enthusiasm and curiosity, their “creative intelligence” processes of listening to clients, analyzing market trends and developing comprehensive programs to fully achieve the clients’ marketing objectives has consistently garnered noteworthy success. For more information, call 949.757.2870 or visit KovachMarketing.com.
Francine Bangert Kovach Marketing firstname.lastname@example.org
Flavor Enhancers Market To Reach USD 11.5 Billion By 2027 | Reports and Data
New York, Aug. 12, 2020 (GLOBE NEWSWIRE) — According to the analysis of Reports and Data, the Global Flavor Enhancers Market was valued at USD 6.6 billion in 2019 and is expected to reach USD 11.5 billion by the year 2027, growing at a CAGR of around 6.5%. According to the Food and Drug Administration (FDA), flavor enhancers are the substances that have no pronounced flavor or taste of their own but which bring out and improve the flavors in the foods to which they are added. The term flavor potentiator has also been used with the same meaning. The most commonly used substances in this category are monosodium L-glutamate (MSG), disodium 5′-inosinate (IMP), and disodium 5′-guanylate (GMP).
The growth of the segment is driven by the expansion of the global beverage industry, an increase in demand for convenience food, changing consumer lifestyle, and an increase in the number of sensory-oriented consumers worldwide. The global flavor enhancers market is expected to witness an upsurge owing to the introduction of new food products with natural ingredients and coloring pigments. Furthermore, technological advancements, growing demand for clean label products, and stringent regulations on synthetic enhancers are influencing manufacturers to incorporate more natural flavors in their offerings. Increasing the use of natural flavor enhancers by the food processing industry is a key factor driving the flavor enhancers market’s growth.
However, factors such as mounting raw material prices and high entry barriers and price pressure on manufacturers due to consolidation affect the industry’s growth. Major trends prevailing in the market are consolidation in the industry, demand for substitutes for artificial flavor enhancers, the emergence of biotech flavor enhancers, and sensory trend.
The global flavor enhancers market is segregated based on type glutamates, acidulants, hydrolyzed vegetable protein, yeast extracts, and others (sweetness enhancers and nucleotides). Based on form, the global flavor enhancers market is segmented in Powder and Liquid & Semi-Liquid. Based on source, the market is segmented into natural and synthetic. Based on application, the market is bifurcated into processed & convenience foods, meat & fish products, beverages, and others (confectionery products, bakery, dairy, and condiments).
Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3408
Further key findings from the report suggest
- By type, the glutamates segment was valued at USD 1.36 billion in 2019. Asia is the largest producer of glutamates, including MSG, accounting for approximately 93% of the global MSG production capacity. Greater demand, an economic and abundant workforce, and its use in processed foods are the prime reasons behind its significant production in Asia. Indonesia, China, Taiwan, Thailand, and Malaysia are the major glutamate manufacturers. China is one of the top manufacturers (66%), the consumer (51%), and exporter (49%) of MSG worldwide. Indonesia is the second-largest (15%) exporter of glutamates. The FDA reported that the Middle East and Africa consumed 4%, Europe 3%, North America 2%, and central and South America 2% MSG.
- Among the application segments, processed & convenience foods occupied a significant share of about 38.3% in the flavor enhancers market. Flavor enhancers like lactic acid find extensive application in the processed & convenience food industry as it benefits from regulating microflora in the food and acting as preservatives. It is formed by the natural fermentation process in food products such as pickled vegetables, cheese, and soy sauce.
- Among the source segments, the natural segment leis growing at a rapid CAGR of 6.8%. The snowballing health awareness among the population and the rising demand for organic foods and upsurge in the buying power of the population fosters the market growth. Offering unique and tastier flavor enhancers would principally boost the demand in the global natural food flavor enhancers market.
- By form, the liquid segment is projected to grow at the fastest CAGR 6.5% during the analysis period. Factors such as minimized ingredient loss, high consistency and uniformity, specification-oriented superior quality production, and excellent microbiological safety drive the market.
- North America occupied a share market share of about 33.5% in 2019 in the flavor enhancers market. Established key market players and continued investments from manufacturers are likely to drive market growth in North America during the forecast period.
- The key players in the market include Tate & Lyle PLC, Cargill, Corbion N.V., Associated British Foods plc, Sensient Technologies, ADM, Novozymes A/S, E.I. Dupont, Angel Yeast Co., Ltd, Innova Flavors, Savoury Systems International, Inc., Senomyx, Inc and Ajinomoto Co, Inc.
- In November 2019, Archer Daniels Midland Co. acquired Florida Chemical Company., which is specialized in citrus-based fragrances and flavors. Florida Chemical Co., a subsidiary of Flotek Industries based in Winter Haven. It offers citrus flavor materials and essential oils as well as flavor enhancers for grapefruit and other citruses.
BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3408
For the purpose of this report, Reports and Data has segmented the Global Flavor Enhancers Market on the basis of type, application, source, form, and region:
Type Outlook (Revenue, USD Billion; 2017-2027)
- Hydrolyzed vegetable protein
- yeast extracts
- Others (sweetness enhancers and nucleotides)
Application Outlook (Revenue, USD Billion; 2017-2027)
- Processed & convenience foods
- Meat & fish products
- Confectionery products
Source Outlook (Revenue, USD Billion; 2017-2027)
Form Outlook (Revenue, USD Billion; 2017-2027)
- Liquid & semi-liquid
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/flavor-enhancers-market
Regional Outlook (Revenue, USD Million; 2017-2027)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of LATAM
- Middle East & Africa
Take a Look at our Related Reports:
Isoflavones Market: https://www.reportsanddata.com/report-detail/isoflavones-market
Krill Oil Market: https://www.reportsanddata.com/report-detail/krill-oil-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: email@example.com
Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
— Companies to jointly validate novel drug targets —
— Scipher eligible for upfront, opt-in and milestone payments —
— Galapagos to progress selected targets into drug discovery —
Mechelen, Belgium and Boston, USA; 12 August 2020 – Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD).
Scipher combines its proprietary Network Medicine Platform with molecular patient data and AI-based methods to identify novel targets and pathways in autoimmune diseases, including IBD.
Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development. Under the terms of the agreement, Scipher is eligible to receive upfront, opt-in and milestone payments and Galapagos will retain the rights for the discovery, development and commercialization of therapeutics for the selected target(s).
“Our breakthrough approach combines extensive patient-level molecular data with AI methods to discover novel targets with the potential to treat specific groups of patients, including those not responding to therapies currently available,” said Alif Saleh, Chief Executive Officer of Scipher Medicine. “This partnership with Galapagos is a recognition of our innovative approach to discover and validate novel targets that could offer a solution for IBD patients.”
“The collaboration with Scipher is aligned with our strategy to discover and develop novel modes of action medicines with the potential to disrupt current treatment paradigms to address high unmet needs in inflammatory diseases,” said Piet Wigerinck, Chief Scientific Officer of Galapagos. “We believe that our drug discovery and development expertise alongside Scipher’s platform will support us in the discovery of exciting new drug candidates.”
About Scipher Medicine
Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests identifying a patient’s unique molecular disease signature and match such signature to most effective therapy ensuring patients receive optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives development of novel and more effective therapeutics. We partner with payers, providers and pharma along the health care value chain to bring precision medicine to autoimmune diseases.
Galapagos NV discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Galapagos Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to diﬀer materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent uncertainties associated with target discovery and validation and drug discovery and development activities (including that data from the ongoing discovery activities may not support the validation of any novel IBD targets or the development of any IBD drug candidates with novel modes of action), expectations regarding the collaboration with Scipher, that Galapagos may decide not to exercise any option granted to it under the agreement with Scipher, and that Galapagos’ expectations regarding the further development of any potential future in-licensed program, including its potential to address a large unmet need in inflammatory diseases, may be incorrect, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended December 31, 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.
VP Investor Relations
+1 781 460 1784
Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
Head of Internal & External Communications & Public Affairs
+32 473 824 874
Senior Director Communications – Therapeutic Areas
+44 7717 801900
Media contacts Scipher Medicine:
OMNIQ Corp. to Host Second Quarter Earnings Call on Friday, August 14, 2020 at 11:00 AM ET
SALT LAKE CITY, Aug. 12, 2020 (GLOBE NEWSWIRE) — OMNIQ Corp. (OTCQB: OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, will host a conference call and webcast on Friday, August 14, 2020 at 11:00 a.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2020.
To access the live webcast, please click on this webcast link to register, or go to the Company’s website at www.questsolution.com, and click on the About tab, then Investors.
To participate in the call by phone, dial (877) 407-9210 approximately five minutes prior to the scheduled start time. International callers please dial (201) 689-8049.
A replay of the teleconference will be available until September 13, 2020 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 36627.
About OMNIQ Corp.
OMNIQ Corp. (OTCQB: OMQS) provides computerized and machine vision image processing solutions that use patented and proprietary AI technology to deliver data collection, real time surveillance and monitoring for supply chain management, homeland security, public safety, traffic & parking management and access control applications. The technology and services provided by the Company help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments. OMNIQ’s customers include government agencies and leading Fortune 500 companies from several sectors, including manufacturing, retail, distribution, food and beverage, transportation and logistics, healthcare, and oil, gas, and chemicals. Since 2014, annual revenues have grown to more than $50 million from clients in the USA and abroad. The Company currently addresses several billion-dollar markets, including the Global Safe City market, forecast to grow to $29 billion by 2022, and the Ticketless Safe Parking market, forecast to grow to $5.2 billion by 2023.
Information about Forward-Looking Statements
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate”, “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products particularly during the current health crisis , the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at http://www.sec.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.
Latest News1 year ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence1 year ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence5 months ago
Special Report: Coronavirus and the Housing Industry
Artificial Intelligence1 year ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence1 year ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence1 year ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence1 year ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence1 year ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation